Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral... Abstract • Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy. References 1. Weiner LP, Stohlman SA, Davis RL: Attempts to isolate viruses from amyotrophic lateral sclerosis . Neurology 1980;30:1319-1322.Crossref 2. Fallis RJ, Weiner LP: Further studies in search of a virus in amyotrophic lateral sclerosis , in Rowland LP (ed): Human Motor Neuron Diseases . New York, Raven Press, 1982, pp 355-361. 3. Johnson RT: Selective vulnerability of neural cells to viral infections , in Rowland LP (ed): Human Motor Neuron Diseases . New York, Raven Press, 1982, pp 331-337. 4. Steward WE II: The Interferon System . New York, Springer-Verlag NY Inc, 1979. 5. Server AC, Wolinsky JS: Approaches to antiviral therapy , in Rowland LP (ed): Human Motor Neuron Diseases . New York, Raven Press, 1982, pp 519-546. 6. Rissanen A, Palo J, Myldylä G, et al: Interferon therapy for ALS . Ann Neurol 1980;7:392.Crossref 7. Färkkilä MA, Iivanainen MV, Bergström L, et al: Interferon treatment in amyotrophic lateral sclerosis . Acta Neurol Scand 1984;98( (suppl 69) ):184-185. 8. Nagata S, Mantei N, Weissmann C: The structure of one of the eight or more distinct chromosomal genes for human interferon-α . Nature 1980;287:401-408.Crossref 9. Rowland LP (ed): Human Motor Neuron Diseases . New York, Raven Press, 1982, pp 1-22. 10. Dalakas MC, Sever JL, Madden DL, et al: Late postpoliomyelitis muscular atrophy: Clinical, virologic, and immunologic studies . Rev Infect Dis 1984;6:562-567.Crossref 11. Dalakas MC, Elder G, Hallett M, et al: A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms . N Engl J Med 1986;314:959-963.Crossref 12. Cantell K, Hirvonen S, Koistinen V: Partial purification of human leukocyte interferon on a large scale . Methods Enzymol 1981;78 ( (pt A) ):499-505. 13. Norris FH, Calanchini PR, Fallat RJ, et al: The administration of guanidine in amyotrophic lateral sclerosis . Neurology 1974;24:721-728.Crossref 14. Mayo Clinic and Mayo Foundation: Clinical Examinations in Neurology , ed 5. Philadelphia, WB Saunders Co, 1981, p 131. 15. Dalakas MC, Papadopoulos NM: Paraproteins in the spinal fluid of patients with paraproteinemic polyneuropathies . Ann Neurol 1984;15:590-593.Crossref 16. Groopman JE, Gottleib MS, Goodman J, et al: Recombinant α2-interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome . Ann Intern Med 1984;100:671-676.Crossref 17. Jablecki C, Cantell K, Connor J, et al: Experimental treatment of ALS with interferon: Pharmacokinetic studies . Ann Neurol 1981;10:82. 18. Iivanainen M, Laakosenen R, Niemi ML, et al: Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis . Acta Neurol Scand 1985;72:475-480.Crossref 19. Mora JS, Kao KP, Munsat TL: Intrathecal interferon in patients with ALS. Neurology, in press. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Loading next page...
 
/lp/american-medical-association/administration-of-recombinant-human-leukocyte-2-interferon-in-patients-K7YxYfSJYI
Publisher
American Medical Association
Copyright
Copyright © 1986 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1986.00520090061018
Publisher site
See Article on Publisher Site

Abstract

Abstract • Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy. References 1. Weiner LP, Stohlman SA, Davis RL: Attempts to isolate viruses from amyotrophic lateral sclerosis . Neurology 1980;30:1319-1322.Crossref 2. Fallis RJ, Weiner LP: Further studies in search of a virus in amyotrophic lateral sclerosis , in Rowland LP (ed): Human Motor Neuron Diseases . New York, Raven Press, 1982, pp 355-361. 3. Johnson RT: Selective vulnerability of neural cells to viral infections , in Rowland LP (ed): Human Motor Neuron Diseases . New York, Raven Press, 1982, pp 331-337. 4. Steward WE II: The Interferon System . New York, Springer-Verlag NY Inc, 1979. 5. Server AC, Wolinsky JS: Approaches to antiviral therapy , in Rowland LP (ed): Human Motor Neuron Diseases . New York, Raven Press, 1982, pp 519-546. 6. Rissanen A, Palo J, Myldylä G, et al: Interferon therapy for ALS . Ann Neurol 1980;7:392.Crossref 7. Färkkilä MA, Iivanainen MV, Bergström L, et al: Interferon treatment in amyotrophic lateral sclerosis . Acta Neurol Scand 1984;98( (suppl 69) ):184-185. 8. Nagata S, Mantei N, Weissmann C: The structure of one of the eight or more distinct chromosomal genes for human interferon-α . Nature 1980;287:401-408.Crossref 9. Rowland LP (ed): Human Motor Neuron Diseases . New York, Raven Press, 1982, pp 1-22. 10. Dalakas MC, Sever JL, Madden DL, et al: Late postpoliomyelitis muscular atrophy: Clinical, virologic, and immunologic studies . Rev Infect Dis 1984;6:562-567.Crossref 11. Dalakas MC, Elder G, Hallett M, et al: A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms . N Engl J Med 1986;314:959-963.Crossref 12. Cantell K, Hirvonen S, Koistinen V: Partial purification of human leukocyte interferon on a large scale . Methods Enzymol 1981;78 ( (pt A) ):499-505. 13. Norris FH, Calanchini PR, Fallat RJ, et al: The administration of guanidine in amyotrophic lateral sclerosis . Neurology 1974;24:721-728.Crossref 14. Mayo Clinic and Mayo Foundation: Clinical Examinations in Neurology , ed 5. Philadelphia, WB Saunders Co, 1981, p 131. 15. Dalakas MC, Papadopoulos NM: Paraproteins in the spinal fluid of patients with paraproteinemic polyneuropathies . Ann Neurol 1984;15:590-593.Crossref 16. Groopman JE, Gottleib MS, Goodman J, et al: Recombinant α2-interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome . Ann Intern Med 1984;100:671-676.Crossref 17. Jablecki C, Cantell K, Connor J, et al: Experimental treatment of ALS with interferon: Pharmacokinetic studies . Ann Neurol 1981;10:82. 18. Iivanainen M, Laakosenen R, Niemi ML, et al: Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis . Acta Neurol Scand 1985;72:475-480.Crossref 19. Mora JS, Kao KP, Munsat TL: Intrathecal interferon in patients with ALS. Neurology, in press.

Journal

Archives of NeurologyAmerican Medical Association

Published: Sep 1, 1986

References